Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Rev3lem1/Cya
Common Name:
Rev3l-KO
Product ID:
S-KO-17672
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Rev3l-KO
Strain ID
KOCMP-19714-Rev3l-B6J-VA
Gene Name
Rev3l
Product ID
S-KO-17672
Gene Alias
Rev; Rev3; Sez4
Background
C57BL/6JCya
NCBI ID
19714
Modification
Conventional knockout
Chromosome
10
Phenotype
MGI:1337131
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Rev3lem1/Cya mice (Catalog S-KO-17672) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000019986
NCBI RefSeq
NM_011264
Target Region
Exon 2
Size of Effective Region
~1.3 kb
Detailed Document
Click here to download >>
Overview of Gene Research
REV3L, encoding the catalytic subunit of DNA polymerase ζ (Pol ζ), is crucial for error-prone translesion synthesis (TLS), a DNA damage tolerance mechanism. TLS helps cells bypass DNA lesions, protecting them from potentially harmful DNA damage, yet it also poses a risk to genome stability due to its error-prone nature [3,4,5,6,7,9].

Multiple studies have shown the significance of REV3L in cancer. In the population of Jammu and Kashmir, three REV3L single-nucleotide variants (rs1002481, rs462779, and rs465646) were significantly associated with an increased risk of non-small cell lung cancer (NSCLC) under the recessive model [1]. In NSCLC H1299 cells, cisplatin induced REV3L expression, and overexpression of REV3L conferred cisplatin resistance, while knockdown sensitized the cells to cisplatin treatment, suggesting REV3L as a potential target for NSCLC chemotherapy [2]. Similar roles were found in esophageal squamous cell carcinoma, gliomas, and cervical cancer, where REV3L was upregulated, associated with tumor progression and chemoresistance [3,5,6]. In myelodysplastic syndrome, a REV3L mutation (c.9253-6T>C) was associated with poor prognosis [8]. Also, in non-small-cell lung cancer, circular RNA PRMT5 promoted cisplatin-resistance via the miR-4458/REV3L axis [10].

In conclusion, REV3L plays a key role in DNA damage tolerance through TLS. Its dysregulation is associated with various cancers, contributing to tumor progression and chemoresistance. Understanding the function of REV3L through these studies provides potential diagnostic and therapeutic targets for multiple cancer types.

References:
1. Jamwal, Rajeshwer Singh, Mahajan, Nikita, Bhat, Gh Rasool, Kumar, Rakesh, Bhat, Audesh. 2021. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir. In Cancer epidemiology, 75, 102047. doi:10.1016/j.canep.2021.102047. https://pubmed.ncbi.nlm.nih.gov/34655923/
2. Wang, Wenjie, Sheng, Wenjiong, Yu, Chenxiao, Zhang, Huojun, Zhang, Shuyu. 2015. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. In Oncology reports, 34, 1460-8. doi:10.3892/or.2015.4121. https://pubmed.ncbi.nlm.nih.gov/26165320/
3. Zhu, Xiaozhong, Zou, Shitao, Zhou, Jundong, Wu, Jinchang, Chen, Yihong. 2016. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma. In Oncology reports, 35, 1664-70. doi:10.3892/or.2016.4549. https://pubmed.ncbi.nlm.nih.gov/26752104/
4. Tirman, Stephanie, Quinet, Annabel, Wood, Matthew, Zou, Lee, Vindigni, Alessandro. . Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. In Molecular cell, 81, 4026-4040.e8. doi:10.1016/j.molcel.2021.09.013. https://pubmed.ncbi.nlm.nih.gov/34624216/
5. Wang, Huibo, Zhang, Shu-Yu, Wang, Shuai, Lu, Daru, Zhao, Shiguang. . REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. In Neuro-oncology, 11, 790-802. doi:10.1215/15228517-2009-015. https://pubmed.ncbi.nlm.nih.gov/19289490/
6. Yang, Li, Shi, Tingyan, Liu, Fei, Yang, Gong, Cheng, Xi. 2015. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. In PloS one, 10, e0120334. doi:10.1371/journal.pone.0120334. https://pubmed.ncbi.nlm.nih.gov/25781640/
7. Halas, Agnieszka, Fijak-Moskal, Jolanta, Kuberska, Renata, Sledziewska-Gojska, Ewa, Płoski, Rafał. 2021. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant. In Journal of molecular medicine (Berlin, Germany), 99, 415-423. doi:10.1007/s00109-020-02033-3. https://pubmed.ncbi.nlm.nih.gov/33474647/
8. Oliveira, Roberta Taiane G de, França, Ivo Gabriel F, Junior, Howard L R, Magalhães, Silvia M M, Pinheiro, Ronald F. 2020. c.9253-6T>c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome. In Hematology, transfusion and cell therapy, 43, 377-381. doi:10.1016/j.htct.2020.05.006. https://pubmed.ncbi.nlm.nih.gov/32682781/
9. Wang, Fengting, Li, Pan, Shao, Yuan, Xiao, Wei, Li, Xialu. . Site-specific proteolytic cleavage prevents ubiquitination and degradation of human REV3L, the catalytic subunit of DNA polymerase ζ. In Nucleic acids research, 48, 3619-3637. doi:10.1093/nar/gkaa096. https://pubmed.ncbi.nlm.nih.gov/32064513/
10. Pang, Jun, Ye, Liwen, Zhao, Dan, Zhao, Ding, Chen, Qingwei. 2020. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer. In Cell biology international, 44, 2416-2426. doi:10.1002/cbin.11449. https://pubmed.ncbi.nlm.nih.gov/32808744/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest